Temat: adalimumab - Prolib Integro

Skocz do pozycji: 1.

Tytuł:: Expression of the BIRC5 gene in the presence of adalimumab in normal human dermal fibroblasts (NHDF)
Autorzy:: Kaźmierczak, Agata
Zmarzły, Nikola
Wcisło-Dziadecka, Dominika
Tematy:: NHDF
adalimumab
survivin; Pokaż więcej
Wydawca:: Przedsiębiorstwo Wydawnictw Naukowych Darwin / Scientific Publishing House DARWIN
Powiązania:: https://bibliotekanauki.pl/articles/1178228.pdf Link otwiera się w nowym oknie
Opis:: Survivin encoded by BIRC5 belongs to the group of proteins that inhibit apoptosis. It consists of the BIR and α-helical C domains. In addition to its inhibitory activity, it plays an important role in cell cycle regulation. Adalimumab is an immunosuppressive drug, a recombinant human anti-TNF-α monoclonal antibody. It is used in the treatment of autoimmune diseases.The aim of the study was to evaluate changes in the expression of BIRC5 and genes encoding apoptosis inhibitors (IAP), depending on the exposure time of the cells to adalimumab. The study material consisted of normal human dermal fibroblasts (NHDF) cultured under standard conditions in the presence of adalimumab (8µg/mL) for 2, 8 and 24 hours. The expression profile of genes associated with apoptosis was determined with the use of HG-U133A 2.0 oligonucleotide microarrays (Affymetrix). The comparative analysis was performed with one-way ANOVA and Tukey's HSD tests (p
Dostawca treści:: Biblioteka Nauki

Artykuł

na półce

Skocz do pozycji: 2.

Tytuł:: Efficacy and safety of biosimilar IFX (CT-P13) and adalimumab in patients with active fistulizing perianal Crohn’s disease naïve to anti-TNF therapy: preliminary results from the POLIBD study
Autorzy:: Pękala, Anna
Aebisher, David
Pardak, Piotr
Filip, Rafał
Tematy:: adalimumab, Crohn’s disease
IFX
perianal fistula; Pokaż więcej
Wydawca:: Uniwersytet Rzeszowski. Wydawnictwo Uniwersytetu Rzeszowskiego
Powiązania:: https://bibliotekanauki.pl/articles/454795.pdf Link otwiera się w nowym oknie
Opis:: Introduction. The development of perianal fistulas are a risk factor in colonic and rectal disease. Perianal CD treatment requires a combination of surgical and therapeutic treatments aimed to prevent septic complications, reduce fistula discharge and ultimately heal fistulas. Aim. The purpose of the study was to evaluate the efficacy and safety of biosimilar IFX (CT-P13) and adalimumab in active fistulizing perianal Crohn’s disease (CD) in patients from the Subcarpathian Region (South-Eastern Poland). Material and methods. Thirty patients with CD with perianal fistulas naïve to anti-TNF therapy were enrolled (13 females/ 17males) ranging from 18 to 64 years of age. Twenty-one were treated with biosimilar infliximab (CT-P13), nine were treated with adalimumab (ADA). The treated patients had ileal CD (4), ileo-colonic CD (13) or colonic CD (13). All of them received standard immunosuppression with no additional steroid therapy. Response was evaluated at week 16 and 40 after the first CT-P13 dose, and 16 and 40 weeks after the first ADA dose. Remission was defined as the complete closure of all fistulas and partial response as a reduction (≥50%) in the number of draining fistulas. Results. Treatment outcomes with CT-P13 and ADA were both effective and similar in the percentage of patients with perianal fistula improvement, perianal fistula remission, no effect or observed adverse events. Conclusion. In patients with active fistulizing CD, both CT-P13 and ADA were effective and safe, however a slight superiority of CT-P13 was visible
Dostawca treści:: Biblioteka Nauki

Artykuł

na półce

Skocz do pozycji: 3.

Tytuł:: Impact of biologic treatment of Cohns disease on the rate of surgeries and other healthcare resources : an analysis of a nationwide database from Poland
Autorzy:: Holko, Przemysław
Kawalec, Paweł
Pilc, Andrzej
Dostawca treści:: Repozytorium Uniwersytetu Jagiellońskiego

Artykuł

na półce

Skocz do pozycji: 4.

Tytuł:: An indirect comparison of infliximab versus adalimumab or golimumab for active ulcerative colitis
Autorzy:: Pilc, Andrzej
Kawalec, Paweł
Opis:: Introduction: The aim of the study was to compare adalimumab or golimumab with infliximab in patients with moderately-to-severely active ulcerative colitis (UC). Material and methods: This paper was prepared according to the PRISMA guidelines. The systematic literature search was performed in PubMed, Embase, and Cochrane Library. No direct head-to-head comparisons for infliximab vs. adalimumab or golimumab were available so an indirect comparison according to the Bucher method was performed after a homogeneity evaluation of the included studies. Results: Six RCTs were included in the systematic review. An indirect comparison was performed, which revealed that infliximab was more effective in inducing clinical response compared with both doses of adalimumab (160/80 mg or 80/40 mg; p < 0.05), and, in clinical remission, infliximab was more effective than adalimumab (only for a dosage regime of 80/40 mg; p < 0.05). No statistically significant differences in clinical response and clinical remission were observed between infliximab and golimumab in the induction phase. A significant (p < 0.05) advantage only of infliximab compared with adalimumab at doses of 80/40 mg and 80/160 mg was seen in terms of clinical response in the maintenance phase (up to 52-54 weeks). The indirect comparison revealed that serious adverse events were significantly more frequent among patients treated with a maintenance dose of 100 mg of golimumab compared with those treated with infliximab (p < 0.05). Conclusions: No significant differences in efficacy in the maintenance phase between infliximab and golimumab or adalimumab were revealed. Infliximab proved to be more effective than adalimumab but of similar efficacy to that of golimumab in the induction phase.
Dostawca treści:: Repozytorium Uniwersytetu Jagiellońskiego

Artykuł

na półce

Skocz do pozycji: 5.

Tytuł:: Skuteczność leczenia przetok w przebiegu choroby Leśniowskiego-Crohna przeciwciałami anty-TNFα
Effectiveness of antiTNFα antibodies in treatment of fistulizing Crohn,s disease
Autorzy:: Przybylska-Feluś, Magdalena
Mach, Tomasz
Zwolińska-Wcisło, Małgorzata
Rozpondek, Piotr
Dostawca treści:: Repozytorium Uniwersytetu Jagiellońskiego

Artykuł

na półce

Skocz do pozycji: 6.

Tytuł:: Adalimumab w terapii nieinfekcyjnych stanów zapalnych błony naczyniowej
Adalimumab therapy of noninfectious uveitis
Autorzy:: Kręcicka, Julia
Turno-Kręcicka, Anna
Misiuk-Hojło, Marta
Tematy:: TNF-α inhibitors
adalimumab
biological therapy
non-infectious uveitis
terapia biologiczna
nieinfekcyjne zapalenie błony naczyniowej
inhibitory anty-TNF-α; Pokaż więcej
Wydawca:: Medical Education
Powiązania:: https://bibliotekanauki.pl/articles/2049383.pdf Link otwiera się w nowym oknie
Opis:: Nieinfekcyjne zapalenia błony naczyniowej (NZBN) stanowią problem diagnostyczny i terapeutyczny, mają przewlekły i kumulacyjny charakter, a także są przyczyną znaczącej utraty funkcji wzroku u młodych osób, uniemożliwiającej aktywność zawodową. Diagnostyka i leczenie wymagają współpracy specjalistów z różnych dziedzin i opierają się na licznych badaniach laboratoryjnych i obrazowych. Praca przedstawia wskazania, efektywność i bezpieczeństwo terapii pierwszym lekiem biologicznym stosowanym w okulistyce, jakim jest inhibitor czynnika martwicy guza α, adalimumab. Może być on uznany za istotną opcję terapeutyczną w leczeniu zapalenia błony naczyniowej części pośredniej i tylnej, a także zapalenia wszystkich części błony naczyniowej, ponieważ pozwala pacjentom na osiągnięcie i utrzymanie długotrwałej kontroli nad chorobą przy jednoczesnej terapii glikokortykosteroidami czy lekami immunomodulującymi lub jej braku.
Noninfectious uveitis is known for its chronic and cumulative nature. It is often associated with diagnostic and therapeutic difficulties. It causes significant vision loss in young patients, making them incapable of maintaining an active work life. Diagnosis and treatment require cooperation between different specialists and are based on multiple blood tests and other diagnostic tests. This article presents medical indications and the safety and efficacy of adalimumab, a tumor necrosis factor inhibitor and the first biological drug used in ophthalmology. Adalimumab is an important therapeutic option for the treatment of intermediate, posterior, and pan-uveitis, enabling patients to obtain and maintain long-term disease control during simultaneous corticosteroid/immunomodulatory therapy or without it.
Dostawca treści:: Biblioteka Nauki

Artykuł

na półce

Informacja

Wyszukujesz frazę "adalimumab" wg kryterium: Temat